Acadia Pharmaceuticals | ACAD - Gross Profit On Sales

Stock Price
23.87
Daily Change
0.41 1.73%
Monthly
-12.97%
Yearly
28.65%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $256.99M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Corcept Therapeutics USD 203.04M 12.04M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
Eisai JPY 151.84B 8.21B Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
J&J USD 16.6B 118M Dec/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 2.42M 38.52M Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025